TITLE

New Cholesterol Cleaner

PUB. DATE
January 2004
SOURCE
Prevention;Jan2004, Vol. 56 Issue 1, p31
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on the low density lipoprotein apheresis treatment. Benefit of the treatment; Procedure of the treatment; Cost of the treatment.
ACCESSION #
11679134

 

Related Articles

  • CVS: Generics essential to reducing health costs. DEARMENT, ALARIC // Drug Store News;8/1/2011, Vol. 33 Issue 10, p30 

    The article focuses on the influence of generic medications for chronic diseases on reducing preventive health care cost. It notes that a study conducted in 2008 indicates that the use of generic drugs in lowering bad low density lipoproteins (LDL) cholesterol cost less compared to the use of...

  • Is newer better in cholesterol drugs?  // Consumer Reports on Health;Aug2003, Vol. 15 Issue 8, p10 

    Discusses the use of two cholesterol-lowering drugs, ezetimibe and extended-release lovastatin. Comparison of effectiveness of ezetimibe and statins; Use of ezetimibe in reducing low density lipoproteins; Advantage of low cost of lovastatin.

  • An Economic Evaluation of Atorvastatin for Primary Prevention of Cardiovascular Events in Type 2 Diabetes. Ramsey, Scott D.; Clarke, Lauren D.; Roberts, Craig S.; Sullivan, Sean D.; Johnson, Scott J.; Liu, Larry Z. // PharmacoEconomics;2008, Vol. 26 Issue 4, p329 

    Objective: The CARDS trial, a multicentre, randomized, controlled trial, found that atorvastatin 10 mg/day for patients with type 2 diabetes mellitus and normal low-density lipoprotein (LDL)-cholesterol significantly reduced cardiovascular (CV) events, including stroke. We estimated the cost...

  • Rosuvastatin STELLAR option for lowering LDL-cholesterol.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p13 

    Discusses research being done on the cost effectiveness of rosuvastatin as a treatment option for the reduction of low density lipoproteins (LDL)-cholesterol in the U.S. Reference to a study by P. H. Chong and D. Varner, published in the February 2005 issue of the "Pharmacotherapy" journal;...

  • A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes. Fox, David; Ried, L. Douglas; Klein, Gary E.; Myers, Wendy; Foli, Kristen // Journal of the American Pharmacists Association: JAPhA;Mar/Apr2009, Vol. 49 Issue 2, p192 

    Objectives: To determine a medication therapy management (MTM) service's impact on (1) Healthcare Effectiveness Data and Information Set (HEDIS) quality measures and (2) use and cost expenditures. Design: Nonequivalent group, quasiexperimental study. Setting: Florida, January 1. 2006. through...

  • Impact of Dyslipidaemia: Lessons from Clinical Trials. Brown, W.V. // PharmacoEconomics;1998 Supplement 3, Vol. 14 Issue 4, p1 

    Coronary heart disease (CHD) is a major cause of morbidity and mortality in Western countries, and is associated with significant healthcare costs. Epidemiological studies have shown that elevated cholesterol levels, particularly elevated low density lipoprotein (LDL) cholesterol, are a major...

  • Reduction in Cardiometabolic Disease Risk Following Gastric Bypass Surgery Among Hispanic Adults. De La Cruz-Muñoz, Nestor; Lopez-Mitnik, Gabriela; Arheart, Kristopher L.; Livingstone, Alan S.; Miller, Tracie L.; Lipshultz, Steven E.; Messiah, Sarah E. // Metabolic Syndrome & Related Disorders;Aug2013, Vol. 11 Issue 4, p262 

    Background: The increasing prevalence of US morbid obesity is associated with serious health consequences and high medical costs, particularly among ethnic minority groups. Little information is available on the long-term weight and chronic disease risk reduction effectiveness of bariatric...

  • Cost-Effectiveness Analysis of Cholesterol-Lowering Therapies in Spain. Plans-Rubió, Pedro // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 3, p177 

    OBJECTIVE: To assess the cost efficacy of atorvastatin, simvastatin, lovastatin, fluvastatin, pravastatin, and colestyramine in the reduction of low-density lipoprotein-cholesterol (LDL-C) levels and the cost per patient to achieve the National Cholesterol Education Program Adult Treatment Panel...

  • How Low Should You Go?  // American Fitness;Nov/Dec2004, Vol. 22 Issue 6, p12 

    Presents information on the results of two 2004 studies about the diets recommended by the National Cholesterol Education Program (NCEP) and the American Heart Association (AHA) in lowering weight and Low Density Lipoprotein-cholesterol in the U.S. Number of people who participated in a study...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics